The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Metronomic chemotherapy (MC) in the neoadjuvant setting: Results of two parallel feasibility trials in patients (pts) with HER2 positive (HER2+) and negative (HER2-) locally advanced breast cancer (LABC) (Traq-Me and TAME).
Vanessa Petry
No relevant relationships to disclose
Alessandro Leal
No relevant relationships to disclose
Roberto J. Arai
No relevant relationships to disclose
Simone Marinho
No relevant relationships to disclose
Marcelo Paiva
No relevant relationships to disclose
Jose R. Piato
No relevant relationships to disclose
Marcio Rosa
No relevant relationships to disclose
Paulo M. Hoff
No relevant relationships to disclose
Max S. Mano
No relevant relationships to disclose